Metabolomics Analysis of Marker Metabolites for Patients with Pancreatic Cancer
Ai-hua Zhang, Hui Sun, Guang-li Yan, Ying Han and Xi-jun Wang*
National TCM Key Laboratory of Serum Pharmacochemistry, Key Laboratory of Metabolomics and Chinmedomics, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China
- *Corresponding Author:
- Xi-jun Wang
National TCM Key Laboratory of Serum Pharmacochemistry
Key Laboratory of Metabolomics and Chinmedomics
Department of Pharmaceutical Analysis
Heilongjiang University of Chinese Medicine
Heping Road 24, Harbin 150040, China
E-mail: [email protected]
Received date: April 25, 2014; Accepted date: June 23, 2014; Published date: June 25, 2014
Citation: Zhang A, Sun H, Yan G, Han Y, Wang X (2014) Metabolomics Analysis of Marker Metabolites for Patients with Pancreatic Cancer. Med chem 4:506-510. doi:10.4172/2161-0444.1000186
Copyright: © 2014 Zhang A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Metabolomics is a rapidly growing field of research used in the identification and quantification of the small molecule metabolites within an organism, thereby providing insights into processes important in clinical medicine. It offers comprehensive information about thousands of low-molecular metabolites (<1500 Da) that represent a wide range of metabolism pathways. In human studies, metabolomics has been applied to define biomarkers related to prognosis or diagnosis of a disease. Pancreatic cancer is a devastating disease and has a very low 5 years-survival rate and its diagnosis is often late and imprecise due to the lack of specificity of currently used markers for pancreatic cancer. Obviously, more sensitive biomarkers for early diagnosis and treatment are urgently needed. Fortunately, metabolomics is becoming increasingly popular, and may provide clinically useful biomarkers applied toward identifying metabolic alterations in pancreatic cancer and has introduced new insights into the pathology of pancreatic cancer. By measuring the endogenous metabolites, metabolomics can be used for delineating metabolic networks and discovering metabolic markers. Studying pancreatic cancer through metabolomics could reveal new biomarkers that could be useful for its future prognosis, diagnosis and therapy. In this review we take a closer look at the metabolomics used within the field of pancreatic cancer disease diagnosis.